Samjin Pharmaceutical (KRX: 005500)
Who is buying Samjin Pharmaceutical?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net sold ₩0.1bn ($0M) of Samjin Pharmaceutical, the 423rd largest foreign net sale among 832 KOSPI stocks. Institutions net sold ₩0.1bn ($0M) and retail investors net bought ₩0.3bn ($0M) over the same window. Foreigners were net buyers on 10 of the 20 sessions.
Foreign investors hold 3.64% of Samjin Pharmaceutical's listed shares (KRX ownership data as of Oct 13, 2026), up from 3.61% twenty sessions earlier and 2.8% a year ago.
The stock closed at ₩19,900 on Oct 13, 2026: +6.59% over 20 sessions, +0.76% year-to-date, +3.32% over one year. The 52-week range is ₩16,580 – ₩25,900.
At ₩19,900 the stock trades at 10.88× 12-month-forward consensus earnings (1 analysts), 10.69× on FY2027 estimates. The trailing P/E published by KRX is 10.14×, based on the last completed fiscal year.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩19,900 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-10-12 | ₩20,100 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-10-08 | ₩20,100 | ₩-0.1bn | ₩0.0bn | +₩0.1bn |
| 2026-10-07 | ₩19,820 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-10-06 | ₩19,320 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-10-02 | ₩19,080 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-10-01 | ₩19,380 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-09-30 | ₩18,750 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-09-29 | ₩18,730 | ₩-0.0bn | ₩-0.1bn | +₩0.1bn |
| 2026-09-28 | ₩18,690 | +₩0.2bn | ₩-0.1bn | ₩-0.2bn |
| 2026-09-23 | ₩18,450 | +₩0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-09-22 | ₩18,460 | +₩0.0bn | +₩0.0bn | ₩-0.1bn |
| 2026-09-21 | ₩18,480 | +₩0.0bn | ₩-0.0bn | ₩-0.0bn |
| 2026-09-18 | ₩18,470 | +₩0.0bn | +₩0.0bn | ₩-0.0bn |
| 2026-09-17 | ₩18,590 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-09-16 | ₩18,550 | ₩-0.1bn | ₩-0.0bn | +₩0.1bn |
| 2026-09-15 | ₩18,390 | ₩-0.1bn | +₩0.0bn | +₩0.0bn |
| 2026-09-14 | ₩18,550 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-09-11 | ₩18,440 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-09-10 | ₩18,550 | ₩-0.1bn | ₩-0.0bn | +₩0.2bn |
| 2026-09-09 | ₩18,670 | +₩0.0bn | +₩0.0bn | ₩-0.0bn |
| 2026-09-08 | ₩18,710 | +₩0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-09-07 | ₩18,780 | +₩0.0bn | ₩-0.0bn | ₩-0.0bn |
| 2026-09-04 | ₩18,750 | ₩-0.1bn | +₩0.0bn | +₩0.1bn |
| 2026-09-03 | ₩18,820 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-09-02 | ₩18,660 | ₩-0.3bn | +₩0.0bn | +₩0.2bn |
| 2026-09-01 | ₩18,820 | +₩0.1bn | +₩0.0bn | +₩0.0bn |
| 2026-08-31 | ₩18,800 | ₩-0.0bn | ₩-0.0bn | ₩-0.0bn |
| 2026-08-28 | ₩18,430 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-08-27 | ₩18,330 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-08-26 | ₩18,550 | +₩0.3bn | ₩-0.0bn | ₩-0.3bn |
| 2026-08-25 | ₩18,060 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-08-24 | ₩18,040 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-08-21 | ₩17,800 | ₩-0.3bn | +₩0.0bn | +₩0.2bn |
| 2026-08-20 | ₩18,020 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-08-19 | ₩17,500 | ₩-0.2bn | +₩0.0bn | +₩0.2bn |
| 2026-08-18 | ₩17,790 | ₩-0.1bn | +₩0.1bn | +₩0.0bn |
| 2026-08-14 | ₩18,440 | +₩0.3bn | ₩-0.0bn | ₩-0.2bn |
| 2026-08-13 | ₩18,270 | ₩-0.3bn | ₩-0.0bn | +₩0.3bn |
| 2026-08-12 | ₩18,450 | ₩-0.3bn | ₩0.0bn | +₩0.3bn |
| 2026-08-11 | ₩18,690 | +₩0.3bn | +₩0.0bn | ₩-0.3bn |
| 2026-08-10 | ₩18,370 | +₩0.3bn | +₩0.0bn | ₩-0.3bn |
| 2026-08-07 | ₩18,300 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-08-06 | ₩18,190 | +₩0.0bn | +₩0.0bn | ₩-0.0bn |
| 2026-08-05 | ₩18,250 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-08-04 | ₩17,850 | +₩0.1bn | ₩-0.0bn | ₩-0.1bn |
| 2026-08-03 | ₩17,650 | ₩-0.1bn | +₩0.0bn | ₩-0.0bn |
| 2026-07-31 | ₩17,730 | +₩0.2bn | ₩-0.0bn | ₩-0.2bn |
| 2026-07-30 | ₩17,060 | +₩0.4bn | +₩0.0bn | ₩-0.4bn |
| 2026-07-29 | ₩17,010 | ₩-0.0bn | ₩-0.0bn | +₩0.0bn |
| 2026-07-28 | ₩17,540 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-07-27 | ₩17,920 | ₩-0.0bn | +₩0.0bn | +₩0.0bn |
| 2026-07-24 | ₩17,870 | +₩0.0bn | +₩0.0bn | ₩-0.0bn |
| 2026-07-23 | ₩17,880 | +₩0.0bn | +₩0.0bn | ₩-0.0bn |
| 2026-07-22 | ₩17,580 | ₩-0.3bn | +₩0.0bn | +₩0.2bn |
| 2026-07-21 | ₩17,750 | +₩0.0bn | +₩0.0bn | ₩-0.0bn |
| 2026-07-20 | ₩17,500 | ₩-0.2bn | ₩-0.0bn | +₩0.2bn |
| 2026-07-16 | ₩17,950 | +₩0.0bn | ₩-0.1bn | +₩0.0bn |
| 2026-07-15 | ₩18,210 | +₩0.3bn | +₩0.1bn | ₩-0.4bn |
| 2026-07-14 | ₩18,200 | +₩0.1bn | +₩0.0bn | ₩-0.1bn |
| 2026-07-13 | ₩18,220 | ₩-0.1bn | ₩-0.0bn | +₩0.2bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | ₩-0.1bn | $-0M | +₩0.0bn | +₩0.1bn |
| 5 days | ₩-0.2bn | $-0M | +₩0.0bn | +₩0.2bn |
| 20 days | ₩-0.1bn | $-0M | ₩-0.1bn | +₩0.3bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Samjin Pharmaceutical stock?
Over the last 5 sessions foreign investors net sold ₩0.2bn ($0M) of Samjin Pharmaceutical; over 60 sessions they net bought ₩0.5bn ($0M); since Jan 1, 2026 they net sold ₩1.6bn ($1M). Over 20 sessions the stock is the 423rd largest foreign net sale among 832 KOSPI stocks.
How much of Samjin Pharmaceutical do foreign investors own?
Foreign investors own 3.64% of Samjin Pharmaceutical's shares as of Oct 13, 2026, versus 2.8% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩0.1bn ($0M) and retail investors net bought ₩0.3bn ($0M) of Samjin Pharmaceutical. Retail investors have been absorbing what foreigners and institutions are selling.
Is Samjin Pharmaceutical listed on KOSPI or KOSDAQ?
Samjin Pharmaceutical (삼진제약) trades on KOSPI under KRX code 005500 in the Biotech & Pharma group, with a market capitalization of ₩0T ($0.2B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩292bn ($219M) | – | ₩20bn ($15M) | ₩19bn ($14M) |
| 2024 | ₩308bn ($231M) | +5.60% | ₩32bn ($24M) | ₩39bn ($29M) |
| 2025 | ₩309bn ($232M) | +0.30% | ₩27bn ($20M) | ₩24bn ($18M) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.